Published in Front Immunol on August 14, 2012
Male Circumcision for HIV Prevention in Rakai, Uganda | NCT00425984
Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men | NCT00458393
HIV Vaccine Trial in Thai Adults | NCT00223080
Effect of Male Circumcision on HIV Incidence (ANRS 1265) | NCT00122525
Investigation of V520 in an HIV Vaccine Proof-of-Concept Study (V520-023) | NCT00095576
Efficacy Study of the Vaginal Gel Carraguard to Prevent HIV Transmission | NCT00213083
Cellulose Sulfate and HIV Transmission Among Women | NCT00153777
HIV Prevention for African American Teens | NCT00279799
Women-Focused HIV Prevention in the Western Cape (WC-WHC) | NCT00729391
Effectiveness of AIDSVAX B/E Vaccine in Intravenous Drug Users in Bangkok, Thailand | NCT00006327
Microbicide Safety and Acceptability in Young Men (Project Gel) | NCT01283360
Safety of Acidform Lubricant in HIV-Uninfected Women | NCT00850837
HIV Prevention Within High-Risk Bulgarian and Hungarian Social Networks | NCT00310973
HIV Prevention Counseling for Men Who Have Sex With Men | NCT00000931
Safety of an Oral HIV Vaccine in HIV Uninfected Volunteers | NCT00062530
Retention and Duration of Activity of SPL7013 (VivaGel®) After Vaginal Dosing. | NCT00740584
Atazanavir or Lopinavir in HIV Post-exposure Prophylaxis | NCT00385645
Selective Exposure in HIV Prevention | NCT01152281
HIV Non Occupational Post-Exposure Prophylaxis (PEP) | NCT00594646
Training Community Members to Deliver HIV Prevention Programs to Urban Youth | NCT00859144
Phenotypes and distribution of mucosal memory B-cell populations in the SIV/SHIV rhesus macaque model. Clin Immunol (2014) 0.87
Noninvasive high-throughput single-cell analysis of HIV protease activity using ratiometric flow cytometry. Sensors (Basel) (2013) 0.83
Design of lipid nanocapsule delivery vehicles for multivalent display of recombinant Env trimers in HIV vaccination. Bioconjug Chem (2014) 0.79
Characterization of antiviral activity of benzamide derivative AH0109 against HIV-1 infection. Antimicrob Agents Chemother (2013) 0.78
Plasma Levels of IFN-γ, IL-4, IL-6 and IL-17 in HIV-Positive Patients With Oral Candidiasis. Jundishapur J Microbiol (2016) 0.77
Allosteric induction of the CD4-bound conformation of HIV-1 Gp120. Retrovirology (2013) 0.76
Simple mathematical models do not accurately predict early SIV dynamics. Viruses (2015) 0.76
A case of lupus-like glomerulonephritis in an HIV patient with nephrotic range proteinuria, purpura, and elevated IgA level. Int J Clin Exp Pathol (2014) 0.75
Epidemiological Distribution and Genotype Characterization of the Hepatitis C Virus Among HIV Patients in Kashan, Iran. Hepat Mon (2016) 0.75
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med (2005) 42.71
Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet (2007) 37.69
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet (2008) 19.65
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science (2009) 17.14
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (2010) 14.91
Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science (1994) 13.54
Estimated HIV incidence in the United States, 2006-2009. PLoS One (2011) 13.03
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol (1996) 11.91
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med (2000) 11.90
Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature (2011) 11.07
A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol (1993) 10.75
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science (2010) 10.69
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis (2005) 10.20
Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature (2011) 9.30
Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science (2005) 9.04
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science (2011) 9.00
Intimate partner violence, relationship power inequity, and incidence of HIV infection in young women in South Africa: a cohort study. Lancet (2010) 8.67
Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol (2001) 8.25
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis (2006) 7.98
Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 7.93
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med (2000) 7.48
Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med (2008) 6.00
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet (2005) 5.75
Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. Lancet (2004) 5.57
A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science (2011) 5.44
Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis (2010) 5.35
HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol (2008) 5.01
Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. Blood (2010) 4.99
Male circumcision for prevention of heterosexual acquisition of HIV in men. Cochrane Database Syst Rev (2009) 4.86
Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med (2009) 4.79
B cells in HIV infection and disease. Nat Rev Immunol (2009) 4.73
Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS (2012) 4.26
PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet (2010) 3.90
Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med (2012) 3.88
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis (2011) 3.71
Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr (2010) 3.58
Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun (2009) 3.38
Immunological mechanisms of vaccination. Nat Immunol (2011) 3.35
Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med (2009) 3.25
Cell-to-cell spread of HIV permits ongoing replication despite antiretroviral therapy. Nature (2011) 3.08
Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS (2011) 2.86
Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment. PLoS Med (2007) 2.85
New horizons in adjuvants for vaccine development. Trends Immunol (2008) 2.85
HIV risk, prevention, and testing behaviors among men who have sex with men--National HIV Behavioral Surveillance System, 21 U.S. cities, United States, 2008. MMWR Surveill Summ (2011) 2.84
Adolescent substance use and sexual risk-taking behavior. J Adolesc Health (2001) 2.84
Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol (2010) 2.76
CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. J Infect Dis (2010) 2.72
Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol (2010) 2.47
Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc Natl Acad Sci U S A (2011) 2.38
Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa. AIDS (2011) 2.38
Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis (2010) 2.28
A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood (2009) 2.25
Electroporation delivery of DNA vaccines: prospects for success. Curr Opin Immunol (2011) 2.25
CpG DNA as a vaccine adjuvant. Expert Rev Vaccines (2011) 2.17
Contemporary costs of HIV healthcare in the HAART era. AIDS (2010) 2.16
Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol (2001) 2.09
Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev (2011) 2.09
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev (2011) 2.07
Enhancement of HIV infection by cellulose sulfate. AIDS Res Hum Retroviruses (2008) 2.04
Designing vaccines based on biology of human dendritic cell subsets. Immunity (2010) 2.04
Alcohol consumption and the intention to engage in unprotected sex: systematic review and meta-analysis of experimental studies. Addiction (2012) 2.04
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res (2009) 2.03
Histone deacetylase inhibitors and HIV latency. Curr Opin HIV AIDS (2011) 2.00
DCs and NK cells: critical effectors in the immune response to HIV-1. Nat Rev Immunol (2011) 1.98
Economic returns to investment in AIDS treatment in low and middle income countries. PLoS One (2011) 1.98
A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J Infect Dis (2008) 1.95
Challenges for structure-based HIV vaccine design. Curr Opin HIV AIDS (2009) 1.91
Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc Natl Acad Sci U S A (2003) 1.88
Assessing vaccine effects in repeated low-dose challenge experiments. Biometrics (2009) 1.85
Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol (2011) 1.80
Fighting HIV/AIDS in Washington, D.C. Health Aff (Millwood) (2009) 1.77
Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine. J Infect Dis (2011) 1.76
The use of nonhuman primate models in HIV vaccine development. PLoS Med (2008) 1.73
The economic burden of late entry into medical care for patients with HIV infection. Med Care (2010) 1.69
Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials. Nat Rev Immunol (2009) 1.68
Clinical applications of DNA vaccines: current progress. Clin Infect Dis (2011) 1.65
Conserved structural elements in the V3 crown of HIV-1 gp120. Nat Struct Mol Biol (2010) 1.63
Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS (2010) 1.62
Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. AIDS Patient Care STDS (2011) 1.60
Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. Cold Spring Harb Perspect Med (2011) 1.58
Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae. J Virol (2010) 1.58
The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr Gene Ther (2008) 1.57
Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines (2010) 1.57
Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology (2008) 1.56
RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther (2009) 1.55
AIDS virus envelope spike structure. Curr Opin Struct Biol (2007) 1.54
Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc Natl Acad Sci U S A (2007) 1.53
Intimate partner violence and HIV among drug-involved women: contexts linking these two epidemics--challenges and implications for prevention and treatment. Subst Use Misuse (2011) 1.52
Functional and phenotypic characterization of the humanized BLT mouse model. Curr Top Microbiol Immunol (2008) 1.50
Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrob Agents Chemother (2007) 1.47
Addressing research priorities for prevention of HIV infection in the United States. Clin Infect Dis (2010) 1.46
Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol (2005) 2.72
A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J Immunol Methods (2005) 2.03
Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunol (2009) 1.93
Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol (2004) 1.83
The use of nonhuman primate models in HIV vaccine development. PLoS Med (2008) 1.73
DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. J Virol (2005) 1.52
Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology (2008) 1.26
Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J Immunol (2006) 1.22
An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains. J Acquir Immune Defic Syndr (2006) 1.21
Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge. J Infect Dis (2005) 1.17
Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia. Vaccine (2011) 1.16
Mucosal immunity and protection against HIV/SIV infection: strategies and challenges for vaccine design. Int Rev Immunol (2009) 1.13
Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization. Vaccine (2010) 1.13
A call for replicating vector prime-protein boost strategies in HIV vaccine design. Expert Rev Vaccines (2004) 1.11
TRIM5α does not affect simian immunodeficiency virus SIV(mac251) replication in vaccinated or unvaccinated Indian rhesus macaques following intrarectal challenge exposure. J Virol (2011) 1.11
Adenoviruses as vectors for HIV vaccines. AIDS Rev (2003) 1.04
Prime-boost vaccination with heterologous live vectors encoding SIV gag and multimeric HIV-1 gp160 protein: efficacy against repeated mucosal R5 clade C SHIV challenges. Vaccine (2011) 1.01
Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development. Expert Opin Biol Ther (2008) 1.00
Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route. Clin Vaccine Immunol (2012) 0.99
Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants. Vaccine (2003) 0.99
Problems and emerging approaches in HIV/AIDS vaccine development. Expert Opin Emerg Drugs (2007) 0.98
Genomic analysis reveals pre- and postchallenge differences in a rhesus macaque AIDS vaccine trial: insights into mechanisms of vaccine efficacy. J Virol (2010) 0.93
A CD8α(-) subpopulation of macaque circulatory natural killer cells can mediate both antibody-dependent and antibody-independent cytotoxic activities. Immunology (2011) 0.91
Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention. Curr HIV Res (2013) 0.90
Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge. Virology (2011) 0.89
NK and CD4+ T cell cooperative immune responses correlate with control of disease in a macaque simian immunodeficiency virus infection model. J Immunol (2012) 0.89
Oral delivery of replication-competent adenovirus vectors is well tolerated by SIV- and SHIV-infected rhesus macaques. Vaccine (2006) 0.88
Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag. Virology (2005) 0.87
Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA. J Immunol (2011) 0.86
Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose. Retrovirology (2014) 0.85
Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques. Virology (2013) 0.83
Early short-term antiretroviral therapy is associated with a reduced prevalence of CD8(+)FoxP3(+) T cells in simian immunodeficiency virus-infected controller rhesus macaques. AIDS Res Hum Retroviruses (2011) 0.83
Immune targeting of PD-1(hi) expressing cells during and after antiretroviral therapy in SIV-infected rhesus macaques. Virology (2013) 0.83
Evaluation of combination DNA/replication-competent Ad-SIV recombinant immunization regimens in rhesus macaques. AIDS Res Hum Retroviruses (2004) 0.83
Rhesus macaque resistance to mucosal simian immunodeficiency virus infection is associated with a postentry block in viral replication. J Virol (2002) 0.82
Replicating Ad-recombinants encoding non-myristoylated rather than wild-type HIV Nef elicit enhanced cellular immunity. AIDS (2006) 0.82
Potent, persistent cellular immune responses elicited by sequential immunization of rhesus macaques with Ad5 host range mutant recombinants encoding SIV Rev and SIV Nef. DNA Cell Biol (2002) 0.81
Strong viremia control in vaccinated macaques does not prevent gradual Th17 cell loss from central memory. Vaccine (2011) 0.81
Enhanced immunity and protective efficacy against SIVmac251 intrarectal challenge following ad-SIV priming by multiple mucosal routes and gp120 boosting in MPL-SE. Viral Immunol (2005) 0.81
Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains. Vaccine (2010) 0.80
High-level, lasting antiviral immunity induced by a bimodal AIDS vaccine and boosted by live-virus exposure: prevention of viremia. AIDS (2012) 0.79
Live recombinant vectors for AIDS vaccine development. Curr Mol Med (2003) 0.79
Insertion of HIV-1 genes into Ad4DeltaE3 vector abrogates increased pathogenesis in cotton rats due to E3 deletion. Virology (2002) 0.79
Antibodies to gp120 and PD-1 expression on virus-specific CD8+ T cells in protection from simian AIDS. J Virol (2013) 0.77
Glucocorticoid treatment at moderate doses of SIVmac251-infected rhesus macaques decreases the frequency of circulating CD14+CD16++ monocytes but does not alter the tissue virus reservoir. AIDS Res Hum Retroviruses (2015) 0.77
High-throughput profiling of anti-glycan humoral responses to SIV vaccination and challenge. PLoS One (2013) 0.76
Effects of intestinal survival surgery on systemic and mucosal immune responses in SIV-infected rhesus macaques. J Med Primatol (2002) 0.75
Corrigendum: Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nat Med (2016) 0.75